WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |

Search International and National Patent Collections
World Intellectual Property Organization
Machine translation
1. (WO2009141729) ANTI-TUMORAL CELLS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2009/141729    International Application No.:    PCT/IB2009/005923
Publication Date: 26.11.2009 International Filing Date: 22.05.2009
C12N 5/16 (2006.01), C12N 15/11 (2006.01), A61K 39/00 (2006.01), C12N 9/12 (2006.01)
Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE [FR/FR]; 3, rue Michel-Ange 75794 Paris Cedex 16 (FR) (For All Designated States Except US).
UNIVERSITE DE MONTPELLIER 1 [FR/FR] (For All Designated States Except US).
HIPSKIND, Robert [US/FR]; (For US Only).
GARAUDE, Johan [FR/FR]; (For US Only).
CHERNI, Seyma [TN/FR]; (For US Only).
DE BETTIGNIES, Geoffrey [FR/FR]; (For US Only).
JACQUET, Chantal [FR/FR]; (For US Only)
Inventors: VILLALBA GONZALES, Martin; .
HIPSKIND, Robert; .
GARAUDE, Johan; .
CHERNI, Seyma; .
DE BETTIGNIES, Geoffrey; .
JACQUET, Chantal;
Agent: DESAIX, Anne; Ernest Gutmann - Yves Plasseraud SAS 3, rue Auber 75009 Paris (FR)
Priority Data:
08/02809 23.05.2008 FR
Abstract: front page image
(EN)The present invention relates to the field of preventive or therapeutic anti- tumoral vaccine. More specifically, the present invention relates to live animal tumour cells having a negative MHC-I phenotype, to methods for the production of such MHC-I negative cells, and to their therapeutic use as anti-tumoral agents, particularly via their capacity to activate natural killer (NK) cells. The invention further relates to methods for modulating the level of expression of MHC-I molecules on animal tumour cells, for example by use of specific culture conditions, and / or by use of exogenous agents which directly or indirectly affect levels of MHC-I expression. The invention also concerns activated NK cells and their therapeutic use as anti-tumoral agents.
(FR)La présente invention concerne le domaine des vaccins anti-tumoraux préventifs ou thérapeutiques. Plus spécifiquement, la présente invention concerne des cellules tumorales animales vivantes ayant un phénotype MHC-I négatif, des procédés de production de telles cellules à MHC-I négatif, et leur utilisation thérapeutique en tant qu’agents anti-tumoraux, notamment par le biais de leur capacité à activer les cellules tueuses naturelles (NK). L’invention concerne également des procédés de modulation du niveau d’expression de molécules MHC-I sur des cellules tumorales animales, par exemple en utilisant des conditions de culture spécifiques et/ou en utilisant des agents exogènes qui affectent directement ou indirectement les niveaux d’expression de MHC-I. L’invention concerne également des cellules NK activées et leur utilisation thérapeutique en tant qu’agents anti-tumoraux.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)